DRRX

Analyst Ratings: Oppenheimer analyst Francois Brisebois has maintained a Buy rating on Durect (DRRX) with a price target of $5.00, while Northland Securities also supports a Buy rating with a target of $8.50, indicating significant upside potential from the current share price of $0.80.

Market Performance: Durect's stock shows a Moderate Buy consensus among analysts, with a one-year high of $1.88 and a low of $0.70, alongside an average return of -6.6% from Brisebois on his recommendations.

Real-time Market Intelligence: Benzinga Pro offers the fastest and most accurate stock market alerts, helping traders stay informed and make winning trades daily.

Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, gaining access to exclusive stories and insights from Benzinga reporters.

DURECT Corporation Updates: DURECT Corporation announced the publication of results from its Phase 2b AHFIRM trial for larsucosterol in treating alcohol-associated hepatitis (AH) in NEJM Evidence, and is planning a Phase 3 trial contingent on funding. The company also reported financial results showing a net income of $7.8 million for Q4 2024 after selling its ALZET product line.

Clinical Trial Insights: The AHFIRM trial highlighted the importance of timely treatment in severe AH patients, with plans for a randomized Phase 3 trial to evaluate larsucosterol's efficacy and safety, aiming to begin in 2025. The FDA has granted larsucosterol Fast Track and Breakthrough Therapy designations due to the lack of approved therapies for AH.

Earnings Report: DURECT reported a Q4 GAAP EPS of $0.24, with revenue declining to $0.45 million, representing a 49.4% decrease year-over-year.

Additional Information: The press release includes references to Seeking Alpha’s Quant Rating and historical earnings data for DURECT.

Earnings Reports: Major companies such as 3D Systems, Cintas, Dollar Tree, and others are set to report earnings today, with expected stock movements indicated by options prices.

Implied Moves: The anticipated stock price changes for companies reporting before and after market close vary significantly, with some companies like DDD and DRRX showing potential moves over 20%.

Upcoming Earnings Reports: Major companies such as GameStop, Lululemon, and Chewy are set to report earnings this week, with TipRanks providing expected stock price movements based on options volatility.

Options Trading Insights: The article explains the concept of "volatility crush," where option prices rise before earnings announcements due to uncertainty and drop significantly afterward, highlighting the risks associated with options trading.

Upcoming Financial Results Announcement: DURECT Corporation will report its fourth quarter and full year 2024 financial results on March 26, 2025, followed by a conference call and webcast for investors at 4:30 PM Eastern Time.

Company Overview and Drug Development: DURECT is focused on developing epigenetic therapies, particularly larsucosterol for acute organ injury, which has received Fast Track and Breakthrough Therapy designations from the FDA.

DURECT Corporation Presentation: DURECT Corporation will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference virtually on February 11, 2025, with CEO James E. Brown speaking from 2:00-2:30 PM ET.

Drug Development and Risks: DURECT is developing larsucosterol for treating alcohol-associated hepatitis and other conditions, but faces potential risks regarding clinical trial outcomes, FDA approvals, and financial stability.

Analyst Rating on Durect: H.C. Wainwright analyst Ed Arce has maintained a Hold rating on Durect (DRRX), with the company's shares currently priced at $0.83 and an analyst consensus of Moderate Buy, targeting an average price of $6.75.

Company Overview: DURECT Corp. is a biopharmaceutical company focused on developing pharmaceutical products, including DUR-928 for inflammation and POSIMIR for post-surgical pain relief, with a current market cap of $25.79M.

Analyst Rating: H.C. Wainwright analyst Ed Arce maintains a Neutral rating on Durect (DRRX) following the publication of Phase 2b trial data for larsucosterol, which showed promising trends in reducing mortality in patients with severe alcohol-associated hepatitis.

Financial Concerns: Despite the positive trial results, there is significant uncertainty regarding financing for the upcoming Phase 3 trial, and Durect faces risks related to its cash runway extending into Q1 of 2025.

DURECT Corporation's Asset Sale: DURECT Corporation has sold its ALZET line of osmotic pumps to Lafayette Instrument Co. for $17.5 million, allowing DURECT to focus on developing larsucosterol for alcohol-associated hepatitis and improving its financial position.

Future Plans and Financial Flexibility: The sale strengthens DURECT's cash reserves and extends its runway into the first half of 2025, as the company prepares for a Phase 3 clinical trial for larsucosterol while eliminating its term loan obligations.

DURECT Corporation's Asset Sale: DURECT Corporation has sold its ALZET line of osmotic pumps to Lafayette Instrument Co. for $17.5 million, allowing DURECT to focus on developing larsucosterol for alcohol-associated hepatitis and improving its financial position.

Future Plans and Financial Flexibility: The sale strengthens DURECT's cash reserves and extends its runway into the first half of 2025, as the company prepares for a Phase 3 clinical trial for larsucosterol while eliminating its term loan obligations.

Fastest News Alerts: Benzinga Pro offers real-time intelligence and news alerts to help traders stay informed and make winning trades in the stock market.

Community of Traders: The platform boasts a community of over 10,000 serious traders who benefit from exclusive stories and accurate market intelligence provided by Benzinga reporters.

Earnings Overview: DURECT Corporation reported total revenues of $1.9 million for Q3 2024, an increase from $1.7 million in the same quarter of 2023, primarily due to higher product sales despite a decline in collaboration revenue.

R&D Expense Reduction: Research and development expenses decreased significantly to $2.2 million in Q3 2024 from $7.2 million in the previous year, attributed to lower spending in this area.

Phase 3 Trial Announcement: DURECT Corporation is preparing to initiate a Phase 3 trial for larsucosterol, aimed at treating severe alcohol-associated hepatitis, with topline results expected within two years, contingent on securing sufficient funding.

Financial Overview: In Q3 2024, DURECT reported total revenues of $1.9 million and a net loss of $4.3 million, while also noting a significant decrease in cash reserves compared to the previous year.

Major Earnings Reports: Key companies reporting earnings after the market close on Wednesday include Cisco Systems, Bionano Genomics, Nu Holdings Ltd., Vaxart, and Canoo.

Additional Earnings Releases: A wide range of other companies are also scheduled to release their earnings reports after Wednesday's close, including ADAP, AEMD, AGRO, and many more.

Financial Results Announcement: DURECT Corporation will report its third quarter financial results on November 13, 2024, followed by a conference call and webcast for investors at 4:30 pm Eastern Time.

Drug Development Update: The company is developing larsucosterol for the treatment of acute organ injury, which has received Fast Track and Breakthrough Therapy designations from the FDA, while also highlighting risks associated with clinical trials and funding.

DURECT Corporation Presentations: DURECT Corporation will present data from its Phase 2b trial of larsucosterol for alcohol-associated hepatitis at The Liver Meeting 2024, highlighting the significance of timely treatment on clinical outcomes.

Company Overview and Future Prospects: DURECT is focused on developing epigenetic therapies for serious conditions, with larsucosterol receiving Fast Track and Breakthrough Therapy designations from the FDA, while also facing potential risks regarding future clinical trials and regulatory approvals.

Aytu BioScience (AYTU): Analyst Naz Rahman from Maxim Group maintains a Buy rating with a price target of $8.00, while the stock currently trades at $2.36, reflecting a Moderate Buy consensus among analysts.

Inventiva (IVA) and Durect (DRRX): Ed Arce from H.C. Wainwright gives Inventiva a Buy rating with a price target of $14.00, indicating a Strong Buy consensus, while Carl Byrnes from Northland Securities rates Durect as a Buy with a target of $8.50, both suggesting significant upside potential from current prices.

Fastest News Alerts: Benzinga Pro offers real-time intelligence and news alerts to help traders stay informed and make winning trades in the stock market.

Exclusive Community: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to exclusive stories and insights from Benzinga reporters.